Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs provides CAR Therapy Discovery & Manufacturing Platforms to support the development of innovative cell therapy products from early research to manufacturing. Our platforms encompass Viral-Based CAR Engineering & Transduction Platforms, Non-Viral CAR Engineering Platforms, and Precision Gene Editing & "Armored" CAR Platforms. By leveraging advanced viral vectors, mRNA-LNP delivery, transposon systems, CRISPR-based gene editing, and immune-enhancing engineering strategies, we enable the generation of customized CAR-T, and other engineered immune cell therapies with improved efficiency, safety, and therapeutic potential.
Advanced viral vector platforms, including lentiviral, retroviral, AAV, adenoviral, and other engineered systems, enable efficient CAR gene delivery, stable expression, scalable immune cell modification, and optimized transduction performance for next-generation CAR therapy development.
Novel versatile non-viral cell engineering systems, which integrate mRNA technology, lipid nanoparticle (LNP) delivery, transposon platforms, nanoparticle transfection and DNA-based engineering tools, enable either temporary or sustained CAR expression in immune cells. These innovative technical systems offer superior safety profiles, more flexible production workflows and a broad spectrum of solutions for the generation of genetically modified immune cells.
Advanced genome editing and armored CAR technologies enable precise genetic modification, enhanced immune cell functions, improved persistence, and resistance to immunosuppressive environments, supporting the development of more effective and durable next-generation CAR therapeutic candidates.
Elevate your CAR therapy programs with Creative Biolabs as your trusted partner. Our tailor-made genetic engineering and full-spectrum development services power faster, more reliable translational progress for your projects. Contact us now to unlock customized solutions and discuss your project roadmap in depth.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
